Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
National Alliance on Mental Illness New Hampshire Janssen Medical Affairs |
---|---|
Information provided by: | National Alliance on Mental Illness New Hampshire |
ClinicalTrials.gov Identifier: | NCT00287027 |
Patients who have schizophrenia, schizoaffective disorder, a psychotic disorder, and are being treated with a medication called Risperidone Long Acting Injectable medication or another antipsychotic medication are candidates for the study. The purpose of the study is to find out from patients' family how they feel the medication has affected their relationship with them. The study will involve meeting with family members three times over the course of one year. The first time will be at New Hampshire Hospital (NHH) or at a community mental health center and the follow up times will be at a convenient place and time for the family member (s), in the community. We will ask them to answer questions from the Family Burden Interview and Quality of Life Questionnaire. The family will not be charged for any test that is completed solely for this study. The family will be provided a travel stipend to meet with the researchers.
Condition | Intervention |
---|---|
Psychotic Disorders |
Drug: Risperdal Long Acting Injectable Antipsychotic Medication |
Study Type: | Observational |
Study Design: | Natural History, Longitudinal, Defined Population, Prospective Study |
Official Title: | Family Perspectives:Treatment of Psychiatric Illnesses With Atypical Long Acting Injectable Antipsychotic Medication |
Estimated Enrollment: | 60 |
Study Start Date: | February 2006 |
Estimated Study Completion Date: | December 2006 |
Patients who have schizophrenia, schizoaffective disorder, a psychotic disorder, and are being treated with a medication called Risperidone Long Acting Injectable medication or another antipsychotic medication are candidates for the study. The purpose of the study is to find out from patients' family how they feel the medication has affected their relationship with them.The study will involve meeting with family members three times over the course of one year. The first time will be at New Hampshire Hospital (NHH) or at a community mental health center and the follow up times will be at a convenient place and time for the family member (s), in the community. We will ask them to answer questions from the Family Burden Interview and Quality of Life Questionnaire. The family will not be charged for any test that is completed solely for this study. The family will be provided a travel stipend to meet with the researchers.We do not see that there will be any risks to the family. We will be interviewing the patient's family, and they will be sharing information as to how they feel their relationship with the patient is going. All efforts will be made to keep this information confidential; however, there may be unforeseen circumstances that could lead to breaching of confidentiality. If the family expresses need for help the research staff will make recommendations for referral to a provider.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Inclusion criteria:Families of adults between the ages of 18-65 who have a diagnosis of Schizophrenia, Schizoaffective Disorder, Psychotic Disorder NOS, and whose loved one gave permission for them to be contacted.
Exclusion Criteria:
-
United States, New Hampshire | |
NAMI NH | |
Concord, New Hampshire, United States, 03301 |
Principal Investigator: | Alex deNesnera, MD | Dartmouth-Hitchcock Medical Center |
Study ID Numbers: | CPHS#17558 |
Study First Received: | February 2, 2006 |
Last Updated: | January 4, 2007 |
ClinicalTrials.gov Identifier: | NCT00287027 History of Changes |
Health Authority: | United States: Food and Drug Administration |
psychotic disorders family burden long acting injectible antipsychotic medication |
Schizophrenia Tranquilizing Agents Mental Disorders Psychotropic Drugs Risperidone |
Central Nervous System Depressants Psychotic Disorders Antipsychotic Agents Schizophrenia and Disorders with Psychotic Features |
Tranquilizing Agents Mental Disorders Therapeutic Uses Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants |
Psychotic Disorders Antipsychotic Agents Central Nervous System Agents Pharmacologic Actions Schizophrenia and Disorders with Psychotic Features |